E2F Decoy solution: Phase III started

Corgentech started PREVENT 4, a 3,000-patient double-blind, placebo-controlled U.S. Phase III trial of its E2F Decoy to prevent graft failure following CABG surgery. E2F Decoy also is in Phase III tes...